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Abstract
Background: Recent studies suggest an association between chronic inflammation, modulating
the tissue microenvironment, and tumor biology. Tumor environment consists of tumor, stromal
and endothelial cells and infiltrating macrophages, T lymphocytes, and dendritic cells, producing an
array of cytokines, chemokines and growth factors, accounting for a complex cell interaction and
regulation of differentiation, activation, function and survival of tumor and surrounding cells,
responsible for tumor progression and spreading or induction of antitumor immune responses and
rejection. Tumor Necrosis Factor (TNF) family members (19 ligands and 29 receptors) represent
a pleiotropic family of agents, related to a plethora of cellular events from proliferation and
differentiation to apoptosis and tumor reduction. Among these members, BAFF and APRIL (CD257
and CD256 respectively) gained an increased interest, in view of their role in cell protection,
differentiation and growth, in a number of lymphocyte, epithelial and mesenchymal structures.
Methods: We have assayed by immunohistochemistry 52 human breast cancer biopsies for the
expression of BAFF and APRIL and correlated our findings with clinicopathological data and the
evolution of the disease.
Results: BAFF was ubiquitely expressed in breast carcinoma cells, DCIS, normal-appearing glands
and ducts and peritumoral adipocytes. In contrast, APRIL immunoreactive expression was higher
in non-malignant as compared to malignant breast structures. APRIL but not BAFF
immunoreactivity was higher in N+ tumors, and was inversely related with the grade of the tumors.
Neither parameter was related to DFS or the OS of patients.
Conclusion: Our data show, for the first time, an autocrine secretion of BAFF and APRIL from
breast cancer cells, offering new perspectives for their role in neoplastic and normal breast cell
biology and offering new perspectives for possible selective intervention in breast cancer.
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Cancer is a hyperproliferative disorder that involves mor-
phological cellular transformation, dysregulation of
apoptosis, uncontrolled cellular proliferation, invasion,
angiogenesis, and metastasis [1]. Clinical and epidemio-
logic studies suggest a strong association between chronic
inflammation and tumor initiation, promotion and pro-
gression [see [2], for a review]. Recent data from mouse
models of human cancer have established that inflamma-
tion, orchestrating the tumor microenvironment, is a crit-
ical component of both tumor promotion and
progression [3,4]. Indeed, the tumor microenvironment
consists of a variable combination of tumor cells, stromal
fibroblasts, endothelial cells and infiltrating leukocytes,
such as macrophages, T lymphocytes, and dendritic cells.
A variety of cytokines, chemokines and growth factors are
produced in the local tumor environment by different
cells accounting for a complex cell interaction and regula-
tion of differentiation, activation, function and survival of
multiple cell types. The interaction between cytokines,
chemokines, growth factors and their receptors forms a
comprehensive network at the tumor site, which is pri-
mary responsible for overall tumor progression and
spreading or induction of antitumor immune responses
and tumor rejection [5].
Current data support the notion that inflammation trig-
gered by tumor-infiltrating host leukocytes does not
always exert normal immunoprotective mechanisms
which could lead to eradication of the evolving cancer
(antitumor immunity). Instead, excessively and chroni-
cally produced proinflammatory mediators are thought to
contribute to tumor promotion and progression [2,3,6,7],
as, in the tumor microenvironment, a delicate balance
occurs between antitumor immunity and tumor-origi-
nated proinflammatory activity [6,8]. These activities
depend on different mediators that are released by host
inflammatory cells, cancer cells, and other types of tumor-
associated host cells (such as fibroblasts and endothelial
cells). When host-mediated antitumor activity is weaker
than tumor-mediated immunosuppressive activity, tumor
cells undergo immune escape and grow rapidly [9]. By
contrast, when host-mediated antitumor immunity is
stronger than tumor-mediated immunosuppressive activ-
ity, tumor cells are eliminated [9]. The net outcome of a
persistent inflammatory microenvironment is enhanced
tumor promotion, accelerated tumor progression, inva-
sion of the surrounding tissues, angiogenesis, and often
metastasis [5].
Several pro-inflammatory cytokines are known to pro-
mote tumor growth, such as tumor necrosis factor -1)
(TNFα), interleukin 1 (IL-1), interleukin 6 (IL-6) or ,
interleukin 8 (IL-8) [4,10]. In addition, a link between
activating mutations in oncogenes and inflammation has
been recently reported, as activation of Ras proto-onco-
genes in cancer results in up-regulation of the inflamma-
tory cytokine IL-8, which, in turn, acts as a chemokine and
in turn promotes tumor associated inflammation, angio-
genesis and eventually tumor growth [11]. The tumor
necrosis factor alpha (TNFα) system is of primary impor-
tance in the modulation of the immune response, sup-
porting the innate immune response by promoting cell
stimulation and pro-inflammatory cytokine secretion.
The TNF superfamily (TNF-SF) consists of 19 ligands and
29 receptors and orchestrates a wide range of biological
functions, from the regulation of activation and cell death
in the immune system to tissue homeostasis and cancer
cell modulation [12]. Recently two new TNF ligands were
discovered through expressed sequence tag (EST) data-
base searches: a proliferation-inducing ligand (APRIL or
CD256, TNFSF13) [13-15] and B lymphocyte stimulator
(BLyS), which is also known as B-cell activating factor of
the TNF family (BAFF, also reported as TALL-1, CD257
and TNFSF13B) [15-18]. Both ligands bind to two TNF-R
family members, transmembrane activator and CAML
interactor (TACI) and B-cell maturation antigen (BCMA
[19], reviewed in [20]). BAFF also specifically binds to
another TNF-R family member, BAFF-R. The interaction
pattern between BAFF, APRIL and their receptors is both
specific and redundant: Binding to their respective recep-
tors leads to the triggering of diverse signaling pathways,
including the activation of caspases, the translocation of
nuclear factor kappaB (NFkappaB), or the activation of
mitogen-activated kinases such as c-Jun NH2-terminal
kinase (JNK) or extracellular signal regulatory kinase
(ERK) [21], (see [22], for a review). BAFF and APRIL were
recently found to be trophic factors in lymphocyte malig-
nancies and immune-related disorders [23], while they
have been identified in bronchial tissue [24], and a
number of immune-rerated and immune-independent
tissues (spleen, liver, lung, heart, intestine, kidney, thy-
mus) [25]. Interestingly, a recent report indicates further
that activation of this system promotes the proliferation
of glioblastoma cell lines [26], while the origin of these
factors in extra-hematologic malignancies is not fully
established. Indeed, both BAFF and APRIL could be syn-
thesized and secreted by B- or T-tumor infiltrating lym-
phocytes, dendritic cells or other components of the
tumor microenvironment [27]. In the present report, we
provide, for the first time, evidence indicating the produc-
tion of these two trophic factors by epithelial breast cancer
cells, indicative for a supplementary autocrine function of
cancer cells. We further report that BAFF is expressed in a
constant way by malignant and peritumoral non-malig-
nant epithelial cells, while the production of APRIL is high
in non-malignant and decreased in malignant breast car-
cinoma cells. In this respect, our data are opposing from
the current dogma of increased APRIL production in
malignancies, suggesting a possible new role of these twoPage 2 of 9
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Fifty two (52) patients, operated for ductal breast cancer
in the Surgical Oncology Department of the University
Hospital of Heraklion, have been included in the present
study. Patients were followed from 2–70 months (overall
survival, median 46 months, mean 44.8 months). Dis-
ease-free survival ranged from 1–69 months (median 46
months, mean 41.5 months). All patients have followed a
pre-operative and post-operative chemotherapy and radi-
otherapy and 40 had an adjuvant hormone therapy. Thir-
teen patients were staged as T1N1M0, 28 patients were
T2N1M0, while the stage of the remaining patients ranged
from T1N0M0 to T3N1M0, according to the tumor size (T),
existence of positive node (N) or distal metastases (M,
each parameter staging from 0 to 3) (Table 1) [28]. An
informed consent was signed by all patients before inclu-
sion in the present study. The Ethics and Scientific com-
mittees of the University Hospital have approved the
present study.
Tumor analysis
All tumor specimens were formalin-fixed and paraffin-
embedded. They were analyzed at the Pathology Depart-
ment of the University of Crete. Three serial sections
(3µm) were cut from each tissue-block. One was stained
with hematoxylin and eosin and two sequential slides
were used for the immunohistochemical detection of
APRIL and BAFF. The slides were reviewed by two investi-
gators independently and blindly to the rest clinicopatho-
logic data, and the final conclusion was reached in
consensus. In few cases with discrepancy, between the two
observers, greater than 10%, the immunostained slides
were reviewed in a double viewing microscope so that the
discrepancy was settled. Histopathological and clinical
data were retrieved from the Pathology and Surgical
Oncology Department databases, including size and
grade of the tumor, TNM status, overall and disease-free
survival and treatment. These data are summarized in
Table 1.
Immunohistochemical Staining for APRIL and BAFF
After deparaffinization and hydration, slides were sub-
jected to three cycles (5 min) of citrate buffer (0.01 M, pH
6.0) incubation in a microwave oven (500 W), and treated
with 3% hydrogen peroxide for 15 min. They were then
incubated with primary antibodies for APRIL (hAprily-8
mouse monoclonal antibody, ALX-804-149, Alexis Co,
Lausen, Switzerland) in a dilution of 1/100, or BAFF (804-
131-C100 monoclonal antibody/Buffy-2 clone, Alexis Co,
Lausen, Switzerland) in a dilution of 1/200. The UltraVi-
sion LP Detection System (TL-060-AL, Lab Vision Co, Fre-
mont, USA) with Fast Red as chromogen was used for
immunodetection. Counterstaining was performed using
controls (omission of the primary antibody) were used in
every run, while a rat or mouse mAB isotype (see Figures
1E and 2E respectively) confirmed the specificity of stain-
ing.
The tumor sections and tissues in their neighbourhood,
included in each one of the whole sections embedded,
were examined and the following components were
recorded: representative areas of the tumor (excluding
necrotic regions), the tumor growing edge, and extratu-
moral structures when present in the tissue block exam-
ined; namely elements of in situ ductal carcinoma (DCIS)
at the vicinity of the invasive component of the carci-
noma, ducts of the mammary tissue with hyperplasia,
normal ducts and lobules The results of the study of each
component studied were reported as a percentage of
stained cells at a given intensity, graded in a scale of 1–3.
The H-score [29] was used for the analysis of results, cal-
culating the intensity and the percentage of staining by the
formula %*1+ %*2+%*3.
Table 1: Clinicopathological characteristics of patients included in the present study
Mean Median Minimum Maximum No of Cases
Age 56.24 58 26 77
Mean Diameter 3.0 2.5 0.8 9.5
Grade 2 1 3
DFS (months) 41.51 46 1 69







T4N1M0 2Page 3 of 9
(page number not for citation purposes)
BMC Cancer 2008, 8:76 http://www.biomedcentral.com/1471-2407/8/76Immunohistochemical staining of BCMA, TACI and BAFF-
R
After deparaffinization and hydration, slides were sub-
jected to three cycles (5 min) of citrate buffer (0.01 M, pH
6.0) incubation in a microwave oven (500 W), and treated
with 3% hydrogen peroxide for 15 min. They were then
incubated with primary antibodies for BCMA (Vicky-1 rat
monoclonal antibody, ALX-804-151, Alexis Co,
Lausanne, Switzerland) in a dilution of 1/100, for TACI
(IMG-249 rabbit polyclonal antibody, Imgenex, San
Diego, CA, USA) in a dilution of 1/100 and for BAFF-R
(AF1162, goat polyclonal antibody, R&D Systems, Minne-
apolis, MN, USA). The UltraVision LP Detection System
(TL-060-AL, Lab Vision Co, Fremont, USA) with Fast Red
as chromogen was used for immunodetection. Counter-
staining was performed using Mayer's hematoxylin.
Known positive and negative controls (omission of the
primary antibody) were used in every run.
Statistical Analysis
Statistical analysis was performed by the use of appropri-
ate parametric and non-parametric tests, as described in
the Results section, by the use of SPSS v 14 and AMOS v6
(SPSS Inc, Chicago, IL). The statistical significance was set-
tled at 0.05.
BAFF immunoreactivity in breast carcinoma (A), DCIS (B, arrowhead)) and normal appearing duct (C, arrow) and lobule (C, arrowhead)Figure 1
BAFF immunoreactivity in breast carcinoma (A), DCIS (B, arrowhead) and normal appearing duct (C, arrow) and lobule (C, 
arrowhead). Normal adipocytes are stained positively for BAFF (Pannel A, arrowhead). In D, a higher magnification is shown, in 
which a homogeneous cytoplasmic BAFF immunoreactivity is shown, with more prominent cell membrane staining. E: Normal 
Ig isotype staining.Page 4 of 9
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Immunohistochemical detection of BAFF and APRIL in 
breast cancer specimens
In the tumor specimens examined, we have further iden-
tified 24 cases with DCIS component, 17 cases with
hyperplastic ducts in the vicinity of the carcinoma, and 9
cases with normal lobules in the neighbourhood of the
main lesion. BAFF was positive in all but one cases of can-
cer, with an H-score ranging from 30–288 (mean = 145,
median 147), in all cases of DCIS (mean H-score = 163,
median 184, range 44–200), in all assayed cases of ducts
(range 145–300) and in all three assayed cases of normal
lobules (H-score range 140–200).
Typical cases are presented in Figure 1. As shown, BAFF
immunoreactivity was detected in the cytoplasm, wherein
some cases a more intense perinuclear staining was
observed. Finally, the periphery of the cells was more
heavily stained. This result is explained by the fact that,
although BAFF is a secreted protein, anchored in the cell
membrane, the thin histological sectioning of our speci-
mens (3 µm) results in an exposure of the BAFF-synthesiz-
ing cytosol to the antibody, expressing an intracellular
staining. Interestingly, peritumoral adipose tissue was
also positive for BAFF staining. Adipocyte cytoplasm and
membranes were always stained for BAFF, while lipid
droplet was negative.
APRIL staining on the other hand, was positive in 39/53
cases of cancer (mean H-score = 60, median = 15, range 2–
282), in 13/15 cases of DCIS (mean H-score = 92, median
= 64, range 6–255), in 7/8 cases of normal ducts (mean H-
APRIL immunoreactivity in invasive breast carcinoma (A), DCIS component of the same carcinoma (B, arrowhead), and normal looking ducts (C, arrow) and lobules (C, arrowhead)Figure 2
APRIL immunoreactivity in invasive breast carcinoma (A), DCIS component of the same carcinoma (B, arrowhead), and normal 
looking ducts (C, arrow) and lobules (C, arrowhead). In D, a higher magnification is shown. APRIL immunoreactivity is pre-
sented as discrete cytoplasmic dots. E: Normal Ig isotype staining.Page 5 of 9
(page number not for citation purposes)
BMC Cancer 2008, 8:76 http://www.biomedcentral.com/1471-2407/8/76score 215, range 110–300) and in 5/5 normal lobules
(mean H-score = 171, range 56–300). In contrast to BAFF,
APRIL immunostaining was restricted in well described
intracellular dots in specific cytoplasmic areas (Figure 2).
Distribution of BAFF-APRIL staining intensity by site of
detection is presented in Figure 3. As shown, BAFF was
equally distributed in cancer and non-cancer sites, sug-
gesting a possible trophic role of the agent in breast tissue.
In contrast, APRIL expression is low in cancer, mediately
elevated in DCIS while it attains its maximum in non-can-
cer breast tissue. This result indicates a differential role of
the two ligands in breast cancer disease and is supported
by the significant dependence of APRIL expression to the
site of detection (p < 0.0001 in both cases, ANOVA with
the Bonferroni correction).
Detection of BAFF-R, BCMA and TACI in breast cancer 
specimens
BAFF and APRIL bind to three different receptors: BAFF-R,
TACI and BCMA [20]. We have assayed these three recep-
tors by immunohistochemistry in subsequent sections on
the same cancer cases. In all cases, the three receptors were
negative (not shown).
Correlation of BAFF and APRIL immunoreactivity with 
clinical data and outcome
As shown in Figure 3A, APRIL immunoreactivity decreases
as normal breast ducts and lobules progress to cancer.
However, a detailed analysis of cancer cases, presented in
Figure 3C reveals a negative, although not significant, rela-
tionship of APRIL immunostaining with the grade of the
tumor (H-score ranging from 102 to 40, Figure 3C). When
cases were stratified according to the existence of lymph-
node metastases, a significant higher APRIL-H-score was
found in N-positive, as compared to N-negative tumors
(H-scores 7.4 ± 5.7 and 65.4 ± 12.0, mean ± SEM for N0
and N1 tumors respectively, t = 4.37, p < 0.0001). In con-
trast, no such a trend is observed in BAFF-immunostain-
ing. No relationship of APRIL- or BAFF-immunostaining
was found however with the DFS or the OS of patients.
Discussion
Current data relay (chronic) inflammation and cancer,
through a complex interplay of autocrine and/or para-
crine interactions of signaling molecules (see [5], for a
recent discussion). Different cytokines, growth and differ-
entiation factors orchestrate both positive and negative
signals for tumor growth, promotion and progression,
angiogenesis and metastasis, secreted by either tumor cells
themselves, stroma cells or infiltrating populations of
lymphocytes and dendritic cells. Among these molecules,
TNF-SF ligands and their cognitive receptors play a pri-
mordial role. The present work reports, for the first time,
the identification of BAFF and APRIL, two members of the
TNF-SF, in breast cancer specimens.
TNF ligand family members are usually synthesized as
type II transmembrane proteins; cleavage is frequently
observed at the plasma membrane. Cleavage usually
occurs in the stalk region between transmembrane and
receptor-binding domains. In contrast to this processing,
APRIL is cleaved intracellularly, which leads to its secre-
tion and not to a membrane-bound form [12,30]. Cleav-
age occurs in the Golgi; blockage of protein transport
from the endoplasmic reticulum to the Golgi apparatus
A. Distribution of APRIL (black bars) and BAFF (gray bars) immunoreactivity in different areas of breast cancer specimensFigure 3
A. Distribution of APRIL (black bars) and BAFF (gray bars) immunoreactivity in different areas of breast cancer specimens. The 
intensity of staining was determined by the use of H-score, as described in the Material and Methods section. Mean ± SEM is 
presented. Asterisk indicates significantly different results (p < 0.05 at least) as determined by ANOVA with post-hoc mean 
comparison, after application of the Bonferroni correction. B. Distribution of APRIL immunoreactivity in node-negative (n = 4) 
and node-positive (n = 35) patients. Mean ± SEM is presented. C. Distribution of APRIL and BAFF immunoreactivity according 
to the Grade of patients. Mean ± SEM is presented.
Figure 3Page 6 of 9
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Golgi transport, does not interfere with APRIL cleavage,
but block secretion of processed APRIL [30]. APRIL
processing is mediated at an arginine-rich motif by furin,
a ubiquitously expressed pro-protein convertase that
processes many inactive precursors including hormones,
growth factors and receptors [31]. BAFF and TWEAK, two
other TNF-SF members, are also cleaved proteolytically at
a multibasic motif, probably by furin [17,32]. In contrast
to APRIL, however, these ligands are not processed intrac-
ellularly, but are instead released from the cell surface,
where they appear as membrane-anchored proteins
[33,34]. Data of the present study are consistent with this
synthetic-secretory pathway. As presented in Figures 1 and
2, APRIL immunoreactivity is presented as discrete intrac-
ellular dots, consistent with vesicle-sequestrated or Golgi-
related ligand, while BAFF immunoreactivity is diffuse in
the (BAFF-synthesizing) cytoplasm and highly concen-
trated at the membrane level.
Most, if not all of the members of the TNF receptor family
activate NFkB and AP-1 via TRAF family of adaptors
[35,36]. However, specific receptors for BAFF and APRIL
(BCMA, TACI, BAFF-R) were not identified in breast can-
cer specimens. Nevertheless, recent reports suggest that
APRIL can additionally bind to heparan sulphate prote-
oglycans (HSPG) on tumor cell surface and initiate tumor
growth [37]. It is interesting to note that this binding
occurs through another part of APRIL molecule, different
from its binding domain, thus permitting the combined
binding to both TACI/BCMA and HSPG. HSPGs play an
important role in a wide variety of biological responses
and processes such as adhesion, migration, proliferation,
embryonal development, differentiation, morphogenesis,
angiogenesis and blood coagulation [38-40], thus linking
APRIL effects to tumor progression. Indeed, preliminary
data indicate that APRIL could enhance migration of
breast cancer cell lines, in vitro. However, there is no cur-
rently established opinion regarding the functional role of
APRIL-proteoglycan interaction: Some authors suggest
that only a ligand oligomerization occurs after APRIL
binding to these membrane structures, facilitating their
interaction with cognitive receptors [41] while others
oppose a discrete receptor-initiated action after such a
binding [37], or a co-receptor activating function of the
APRIL-HSPG dimer [42] or HSPG themselves [43].
Until now, very scarce data exist on the identification of
the BAFF/APRIL system in breast carcinoma. Hahne et al
[13] reported that APRIL could not elicit any proliferative
effect on MCF7 breast cancer cells, in contrast to other
cancer cell lines from different tissues, providing a hint for
the decreased expression of APRIL in breast tumor speci-
mens, reported here. Interestingly, APRIL expression in a
number of solid tumors was attributed to infiltrating lym-
phocytes, while scare tumor types, especially cutaneous
carcinomas, overexpressed the ligand [44]. It is interesting
to note that in the same study 2159 tumors of different
origins (including 130 breast carcinomas) have been
assayed. Only 20 tumors expressed APRIL, in the absence
of stroma staining, while 50 tumor stroma expressed
exclusively APRIL, in the absence of epithelial staining.
The authors suggest that APRIL expression in solid tumors
might be a result of a response to an exogenous factor
(stimulus) than an intrinsic property of the tumor. How-
ever, taking into account the results of previous [44] and
of the present study (absence of BAFFR, BCMA and TACI),
a possible interaction with heparin-sulphate proteogly-
cans may be suggested. In this context, as discussed previ-
ously [44], APRIL-HSPG interaction may represent a
paracrine growth-stimulating function, inducing tumor
growth [44,45].
Previous data indicate that APRIL, in contrast to many
other TNF-related ligands, is a factor promoting survival
of tumor cells in tissue culture and when human tumors
are transplanted into immune-deficient mice [13].
Indeed, the expression of APRIL was reported to be nearly
undetectable in normal tissue but dramatically elevated in
tumors. Addition of recombinant APRIL or transfection of
tumor lines with APRIL provided a significant growth
advantage to lymphoid and nonlymphoid cells [46]. This
suggests that APRIL expression may be a consequence of
the stress of malignant transformation [27,44]. Our data
show, however, that this general concept does not apply
to the breast. Indeed, we show for the first time, a direct
production of APRIL from the breast non-tumoral epithe-
lium, inversely related to the malignant transformation of
cells, suggesting a possible role of APRIL in well differen-
tiated mammary cells and a decline of its production dur-
ing malignant transformation. This is further verified, as a
negative (although not-significant) trend of APRIL immu-
noreactivity with the grade of the tumor is also found.
Alternatively, if the general concept of APRIL up-regula-
tion as a consequence of stress applies equally in the
breast, overproduction of the ligand by peritumoral cells
might be due to the physical and/or humoral stress
exerted on normal cells by the growing tumor. It might
therefore be interesting to follow the evolution of APRIL
production in different breast carcinoma cells, represent-
ing different evolutionary stages of breast cancer and its
modulation with (chemo)therapy or under the action of
factors affecting breast cell biology. Such an investigation
is currently under progress. In contrast to APRIL, we report
for the first time that BAFF is ubiquitously expressed in
breast carcinomas, DCIS, normal ducts and lobules with
the same intensity, indicating a possible trophic effect of
the agent in breast tissue. Alternatively, BAFF could be a
constitutively expressed protein of the breast epithelial tis-
sues and derived carcinomas.Page 7 of 9
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also constitutively expressed by adipocytes surrounding
the tumor lesions. Adipose tissue has long been regarded
as an almost resting tissue, dedicated solely to energy stor-
age and release. However, in recent years, this view has
changed dramatically following new insights into the
metabolic and immunological functions of preadipocytes
and adipocytes. Indeed, these cells are potent producers of
proinflammatory cytokines (such as IL-6 and TNF) and
chemokines. Furthermore, adipocytes secrete high
amounts of adipokines, such as leptin, adiponectin and
resistin, regulating monocyte/macrophage function, and
molecules associated with the innate immune system,
such as the C1qTNF-related protein superfamily. Finally,
preadipocytes and adipocytes express a broad spectrum of
functional Toll-like receptors and can be converted into
macrophage-like cells [reviewed in [47]]. These data
clearly establish the role of adipose tissue as a new mem-
ber of the immune system. Adipocytes were found to
secrete and be sensible in an autocrine way to TNF, via
TNFR1 activation [48]. The role of the cytokine was to
suppress adipogenesis and to induce apoptosis [49]. Here,
however, we show that peritumoral adipocytes synthesize
in a constitutive way BAFF, a ligand which, upon binding
to its cognitive receptor, induces survival and differentia-
tion of other cell lineages [35], supporting a possible new
trophic role of breast adipocytes in the development of
breast epithelium. It might therefore be interesting to
investigate under a new light the functional interplay of
both the BAFF/APRIL system expression and biological
functions in adipose tissue proliferation and survival and
the role of adipocytes in mammary gland development,
function and malignant transformation.
APRIL and BAFF immunoreactivity does not seem to
derive from inflammatory cell infiltration of the tumor.
Indeed, as presented, no lymphocyte infiltration of
tumors was evident in our specimens. It might therefore
be attributed to an auto/paracrine secretion of these
agents by the breast tissue itself. In addition this immuno-
reactivity is not related to the outcome of breast cancer
patients. Indeed, no significant relationship between
BAFF or APRIL H-scores with overall- or disease-free sur-
vival of patients was detected. However, APRIL immuno-
reactivity was higher in tumors metastasized to lymph
nodes, as compared to non-metastasized cases. It is not
obvious however, whether this is a causal effect of APRIL,
being a lymphocyte proliferation factor [35], or a conse-
quence of metastasized tumors.
Conclusion
The arising question, in view of our data, is which might
be the functional role of the TNF-related system of BAFF-
APRIL in breast cancer. The rarity of reported results on
their role in epithelial cancers and especially in breast car-
cinoma does not allow us to proceed to an established
evaluation of the system in cancer biology. Indeed, BAFF
and APRIL may act as tumor promoters in different sys-
tems they have been examined. Our results, however,
indicate that the constant expression of BAFF, in adi-
pocytes, normal breast cells and their cancer counterparts,
might be relevant of the trophic potency in breast, pro-
moting the proliferation and development of normal and
malignant breast tissue. In contrast, the decreased expres-
sion of APRIL in breast cancer, as compared to non-cancer
breast structures, suggests a possible negative role of this
factor in breast neoplasia progression. Our data provide
new hints about the possible role of BAFF/APRIL in nor-
mal and neoplastic breast tissue and possibly other epi-
thelial or mesenchymal structures. They further offer new
perspectives on their possible application as new targets
for selective therapeutic intervention.
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